ST elevation myocardial infarction anticoagulant and antithrombotic therapy: Difference between revisions
No edit summary |
|||
| Line 43: | Line 43: | ||
Ximelogatran (removed from market) | Ximelogatran (removed from market) | ||
====Parenteral Drugs Targeting Both Factor IIa and Factor Xa==== | |||
Enoxaperin inhibits Factor Xa more than IIa | |||
Unfractionated heparin inhibits Factor IIa more than Xa | |||
==References== | ==References== | ||
Revision as of 00:17, 22 April 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] As an active clinical researcher, Dr. Gibson has received research and grant support from the majority of manufacturers of antithrombin and antiplatelet agents. You can view his complete disclosure statement here.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Management of the patient with ST elevation myocardial infarction requires inhibition of both the the generation of thrombin (i.e inhibition of the coagulation cascade via antithrombins) as well as the platelet (via antiplatelet agents). Selection of the appropriate antithrombin depends upon a variety of factors including the choice of revascularization strategy. This chapter reviews data supporting the use of both parenteral antithrombotic and oral antithrombotic (anticoagulant) agents.
Sites of Action of Antithrombins
The majority of established and investigational antithrombins target two factors in the coagulation cascade: Factor Xa and Factor II. [1] factor Xa lies higher in the coagulation cascade at the intersection of the intrisic and extrinsic pathway. Inhibition of Factor Xa limits the initial thrombin generation irrespective of whether the coagulation cascade was initiated by the intrinsic or extrinsic pathway. Factor II (thrombin) lies lower in the coagulation cascade and is involved in the conversion of fibrinogen to fibrin.
Parenteral Drugs Targeting Factor Xa
Indirect Inhibitors Requiring Antithrombin
Idraparinux
Direct Inhibitors Not Requiring Antithrombin
DX-9065a
Otamixaban
Oral Drugs Targeting Factor Xa
Rivaroxaban
Apixaban
LY517717
YM150
DU-176b
PRT-054021
Parenteral Drugs Targeting Factor IIa
Oral Drugs Targeting Factor IIa
Dabigatran
Ximelogatran (removed from market)
Parenteral Drugs Targeting Both Factor IIa and Factor Xa
Enoxaperin inhibits Factor Xa more than IIa
Unfractionated heparin inhibits Factor IIa more than Xa
References
- ↑ Weitz JI (2006). "Emerging anticoagulants for the treatment of venous thromboembolism". Thromb. Haemost. 96 (3): 274–84. doi:10.1160/TH06-05-0234. PMID 16953267. Unknown parameter
|month=ignored (help)